Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 November 2024 | Story André Damons | Photo André Damons
Khoebo Innovation Promotion Programme launch 2024
Staff members from the Directorate Research Development (DRD) at the University of the Free State; Palesa Mgaga, second from right, Tebogo Machethe, centre, and Charelise van Staden, second from right, were thanked for hosting the launch of the Khoebo Innovation Promotion Programme. They are pictured with colleagues from the IDC’s Samkelisiwe Mtsewu, left, and Thato Mogopodi, far right.

The University of the Free State (UFS), represented by the Directorate Research Development (DRD), played host to the Department of Trade Industry and Competition (dtic) and the Industrial Development Corporation (IDC) for the launch of its Khoebo Innovation Promotion Programme (KIPP).

The launch took place on 5 November in the Sasol Library on the Bloemfontein Campus. Tebogo Machethe, Director: Research Contracts and Innovation at the DRD, said its role was to expose the university researchers to different opportunities and programmes for funding from the IDC and the dtic. It also allowed the researchers to engage potential funders in order to understand what funders look for in a project when considering funding it.

“The aim of IDC KIPP is to assist local entrepreneurs and small to medium enterprises with commercialisation funding. The KIPP offers capital and business support to SMMEs during the early stages of commercialisation with particular emphasis on township and rural entrepreneurs,” said Machethe.

Address uneven distribution of economic development

KIPP is a dtic programme but is managed by the IDC and aims to enable early-stage innovative SMEs to penetrate the market with their locally developed innovations, resulting in a more competitive economic environment and thereby facilitating economic growth in the economy.

According to Machethe, who welcomed the guests, participants and presenters to the launch, some of the funding is geared towards the development of university innovations. Though the focus was on the KIPP launch, he continued, the discussions also encompassed other forms of funding that are available and more geared towards the university innovation.

His address was centred around the university's Vision 130 and how it supports innovation and the entire innovation ecosystem, which seeks to shift the emphasis to research impact, embracing both knowledge and societal impact. Vision 130 identifies the need for a greater focus on collaborative research, research that can attract large-scale funding in niche areas where the university is seen as a national and global leader.

Samkelisiwe Mtsewu, KIPP Account Manager at the IDC, said the programme was introduced to address the uneven distribution of economic development across the country. She said with its capacity, the KIPP programme can contribute to addressing the uneven distribution of economic development. 

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept